Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Selexipag in Healthy Male Subjects
NCT02882425Phase 1Completed
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Jan 2015
- Primary completion
- Apr 2015
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of selexipag in pulmonary arterial hypertension (PAH) (3 arms), sponsored by Actelion Pharmaceuticals Ltd. Primary endpoints: Absolute bioavailability (F) of selexipag and Area under the plasma concentration-time curve from time 0 to infinity. Started Jan 2015; status: completed.
02
Drugs
selexipag
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT02882425.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02882425.